XML 84 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Significant accounting policies - Additional Information (Detail)
 1 Months Ended 12 Months Ended
Aug. 07, 2023
AUD ($)
Aug. 07, 2023
USD ($)
Jun. 30, 2023
AUD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
AUD ($)
Jun. 30, 2022
USD ($)
Jun. 30, 2021
AUD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2022
USD ($)
May 01, 2022
USD ($)
Jul. 01, 2021
AUD ($)
Jun. 30, 2020
AUD ($)
Disclosure of summary of significant accounting policies [line items]                        
Consolidated loss after income tax     $ 20,465,180   $ 25,014,055   $ 8,420,000          
Net current asset position     3,207,572   2,720,664              
Net cash outflows from operating activities     15,156,157   22,762,663              
Consolidated cash in hand and at bank     5,241,197   7,361,112   27,587,000       $ 27,587,000 $ 8,764,000
Proceeds from issuing shares     $ 12,972,000   $ 3,726,000   $ 28,109,000          
At The Market Equity Program [Member]                        
Disclosure of summary of significant accounting policies [line items]                        
Aggregate offering                   $ 35,000,000    
Proceeds from issuing shares       $ 4,203,221   $ 2,956,036            
American Depository Shares [Member] | At The Market Equity Program [Member]                        
Disclosure of summary of significant accounting policies [line items]                        
Number of shares represented by one depositary receipt                   10    
Net amount eligible to be offered for issue               $ 27,800,000 $ 32,040,000.00      
Major ordinary share transactions [member] | At The Market Equity Program [Member]                        
Disclosure of summary of significant accounting policies [line items]                        
Proceeds from the issuance of common stock $ 1,540,918 $ 1,019,769                    
Licensing agreement for paxalisib [member]                        
Disclosure of summary of significant accounting policies [line items]                        
Remaining useful life,licensing agreement     15 years 15 years                
Licensing agreement for EVT801 [member]                        
Disclosure of summary of significant accounting policies [line items]                        
Remaining useful life,licensing agreement     12.5 years 12.5 years